Last updated: June 2021

Prescription under medical supervision

Therapeutic action

– First line antituberculosis antibacterial (sterilising and bactericidal activity)


– Tuberculosis, in combination with other antituberculosis antibacterials

Forms and strengths

– 400 mg tablet
– 150 mg dispersible tablet


– Child under 30 kg: 35 mg/kg (30 to 40 mg/kg) once daily
– Child 30 kg and over and adult: 25 mg/kg (20 to 30 mg/kg) once daily
– Do not exceed 2 g daily.
– Patient with renal impairment: 25 mg/kg 3 times weekly


– According to protocol

Contra-indications, adverse effects, precautions

– Do not administer to patients with hypersensitivity to pyrazinamide, severe hepatic impairment or severe gout.
– May cause: gout and arthralgias, hepatotoxicity, photosensitivity (limit sun exposure), rash, gastrointestinal disturbances, hypersensitivity reactions.
– Monitor liver function in patients with known hepatic disease.
– If signs of hepatotoxicity (e.g. jaundice) develop, pyrazinamide should be discontinued until symptoms resolve.
Pregnancy: no contra-indication
Breast-feeding: no contra-indication


– For patients on first-line antituberculosis treatment, pyrazinamide is given as part of a fixed dose combination.
Storage: below 25 °C -